Plasma levels of S100A9 were also increased in SSc patients [161], and since S100A9 induces fibroblast proliferation and fibroblast production of connective tissue growth factor (CTGF/CCN2) through Toll-like receptors, it likely contributes to the development of tissue fibrosis in SSc [163]. Here, CCN2 is linked to systemic sclerosis.